Stocks and Investing
Stocks and Investing
Fri, September 15, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Joseph Pantginis Maintained (BLRX) at Strong Buy with Increased Target to $21 on, Sep 15th, 2023
Joseph Pantginis of HC Wainwright & Co., Maintained "BioLineRx Ltd." (BLRX) at Strong Buy with Increased Target from $19 to $21 on, Sep 15th, 2023.
Joseph has made no other calls on BLRX in the last 4 months.
There is 1 other peer that has a rating on BLRX. Out of the 1 peers that are also analyzing BLRX, 0 agree with Joseph's Rating of Hold.
This is the rating of the analyst that currently disagrees with Joseph
- Mark Breidenbach of "Oppenheimer" Reiterated at Buy and Held Target at $4 on, Thursday, May 25th, 2023
Contributing Sources